Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters
10.1126/science.276.5315.1119
Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

Prion diseases are transmissible neurodegenerative conditions characterized by the accumulation of protease-resistant forms of the prion protein (PrP), termed PrPres, in the brain. Insoluble PrPres tends to aggregate into amyloid fibrils. The anthracycline 4′-iodo-4′-deoxy-doxorubicin (IDX) binds to amyloid fibrils and induces amyloid resorption in patients with systemic amyloidosis. To test IDX in an experimental model of prion disease, Syrian hamsters were inoculated intracerebrally either with scrapie-infected brain homogenate or with infected homogenate coincubated with IDX. In IDX-treated hamsters, clinical signs of disease were delayed and survival time was prolonged. Neuropathological examination showed a parallel delay in the appearance of brain changes and in the accumulation of PrPres and PrP amyloid.

Bibliography

Tagliavini, F., McArthur, R. A., Canciani, B., Giaccone, G., Porro, M., Bugiani, M., Lievens, P. M.-J., Bugiani, O., Peri, E., Dall’Ara, P., Rocchi, M., Poli, G., Forloni, G., Bandiera, T., Varasi, M., Suarato, A., Cassutti, P., Cervini, M. A., Lansen, J., … Post, C. (1997). Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters. Science, 276(5315), 1119–1121.

Authors 21
  1. F. Tagliavini (first)
  2. R. A. McArthur (additional)
  3. B. Canciani (additional)
  4. G. Giaccone (additional)
  5. M. Porro (additional)
  6. M. Bugiani (additional)
  7. P. M.-J. Lievens (additional)
  8. O. Bugiani (additional)
  9. E. Peri (additional)
  10. P. Dall’Ara (additional)
  11. M. Rocchi (additional)
  12. G. Poli (additional)
  13. G. Forloni (additional)
  14. T. Bandiera (additional)
  15. M. Varasi (additional)
  16. A. Suarato (additional)
  17. P. Cassutti (additional)
  18. M. A. Cervini (additional)
  19. J. Lansen (additional)
  20. M. Salmona (additional)
  21. C. Post (additional)
References 36 Referenced 134
  1. 10.1126/science.1675487
  2. ; Annu. Rev. Microbiol. 48 655 (1994). (10.1146/annurev.mi.48.100194.003255)
  3. Caughey B.W., et al., Biochemistry 30, 7672 (1991); (10.1021/bi00245a003) / Biochemistry by Caughey B.W. (1991)
  4. 10.1073/pnas.90.23.10962
  5. Safar J., Roller P. P., Gajdusek D. C., Gibbs C. J., J. Biol. Chem. 268, 20276 (1993); (10.1016/S0021-9258(20)80725-X) / J. Biol. Chem. by Safar J. (1993)
  6. Prusiner S. B., et al., Cell 35, 349 (1983); (10.1016/0092-8674(83)90168-X) / Cell by Prusiner S. B. (1983)
  7. DeArmond S. J., et al., ibid. 41, 221 (1985). / ibid. by DeArmond S. J. (1985)
  8. Bruce M. E., McBride P. A., Farquhar C. F., Neurosci. Lett. 102, 1 (1989); (10.1016/0304-3940(89)90298-X) / Neurosci. Lett. by Bruce M. E. (1989)
  9. ; S. J. DeArmond et al. in Prion Diseases of Humans and Animals S. B. Prusiner J. Collinge J. Powell B. Anderton Eds. (Horwood London 1992) pp. 483–496;
  10. DeArmond S. J., et al., Proc. Natl. Acad. Sci. U.S.A. 90, 6449 (1993); (10.1073/pnas.90.14.6449) / Proc. Natl. Acad. Sci. U.S.A. by DeArmond S. J. (1993)
  11. Forloni G., et al., Nature 362, 543 (1993); (10.1038/362543a0) / Nature by Forloni G. (1993)
  12. Forloni G., et al., Eur. J. Neurosci. 6, 1415 (1994); (10.1111/j.1460-9568.1994.tb01003.x) / Eur. J. Neurosci. by Forloni G. (1994)
  13. Brown D. R., Schmidt B., Kretzschmar H. A., Nature 380, 345 (1996). (10.1038/380345a0) / Nature by Brown D. R. (1996)
  14. Ingrosso L., Ladogana A., Pocchiari M., J. Virol. 69, 506 (1995). (10.1128/jvi.69.1.506-508.1995) / J. Virol. by Ingrosso L. (1995)
  15. Caughey B., Race R. E., J. Neurochem. 59, 768 (1992). (10.1111/j.1471-4159.1992.tb09437.x) / J. Neurochem. by Caughey B. (1992)
  16. Barbieri B., et al., Cancer Res. 47, 4001 (1987). / Cancer Res. by Barbieri B. (1987)
  17. Gianni L., Bellotti V., Gianni A. M., Merlini G., Blood 86, 855 (1995). (10.1182/blood.V86.3.855.855) / Blood by Gianni L. (1995)
  18. Merlini G., et al., Proc. Natl. Acad. Sci. U.S.A. 92, 2959 (1995). (10.1073/pnas.92.7.2959) / Proc. Natl. Acad. Sci. U.S.A. by Merlini G. (1995)
  19. Samples of the cerebrum and cerebellum from Syrian hamsters infected with the 263K strain of scrapie and from patients with sporadic Creutzfeldt-Jakob disease and amyloid deposits were fixed in 10% formaldehyde and embedded in paraplast. Adjacent sections (8 μm thick) were stained with 1% thioflavine S for amyloid or were incubated with 10 –7 M aqueous solution of IDX for 1 hour at 37°C washed for 30 min with 150 mM phosphate-buffer (pH 7.2) and counterstained with Meyer’s hematoxylin. The sections were analyzed by fluorescence microscopy (excitation and barrier filters: 436 and 520 nm for thioflavine S; 546 and 580 nm for IDX).
  20. The hamsters were housed in groups of four to six animals in a temperature-controlled (20° ± 2°C) quarantined room maintained on a 12-hour light-dark cycle (the light was on from 0600 to 1800). They were allowed free access to food and water and their body weight was recorded once a week. The animals were observed by research staff who were unaware of the individual treatment conditions according to a block design in which each block of observations included each treatment condition. The scoring of observational data was carried out as follows. Balance and coordination were evaluated by (i) the ability of the hamster to remain on a narrow plank (a ruler) and (ii) the ability to land on four paws after falling from a thin wire. Posture and tremors were evaluated by observation. The behaviors were scored according to discrete item-ordinate scales as follows. Balance: 0 normal; 1 impaired; 2 unstable; and 3 loss. Posture: 0 normal; 1 abnormal; 2 limbs abducted; and 3 hunchback. Tremors: 0 absent; 1 mild; 2 present; and 3 increased. In order to quantify and analyze these behaviors the following convention was adopted: The experiment was operationally defined as the period from the day of infection to the day of death of the last scrapie-infected hamster (day 144 after infection). The data from hamsters killed for neuropathological and biochemical examination were excluded from the analysis and death was considered a behavioral state within the definition of the experiment. The number of days in which each hamster was in a particular state of behavior (normal increased reduced absent or dead) was counted. As behavioral observations took place at intervals rather than daily an estimate of the behavioral stage between observations was made by assigning the same score within each day if the score at each limiting observational day was the same. Otherwise if the behavioral score between one observational day and another changed then half of the intervening days were assigned the lower score and half of the intervening days were assigned the higher score. These data were then analyzed according to a split-plot factorial design with the treatment group being the independent factor and the state of behavior factor being repeated. The cage leaving behavior of the hamsters was observed and recorded by video in a rectangular cage (22 by 36 by 12 cm). Recording sessions were carried out before infection and at various days after infection. The observation period lasted a maximum of 180 s. Post-hoc paired comparisons between means were evaluated by Tukey’s q method for multiple comparisons where * = P < 0.05 and ** = P < 0.01 from infected controls.
  21. For neuropathological and biochemical examination four hamsters from each group were killed (according to the Policy on the Use of Animals in Neuroscience Research of the Society for Neuroscience) when behavioral changes were first apparent in the infected controls. The remaining hamsters were analyzed after dying at the terminal stage of the disease. The left cerebral hemisphere was frozen and stored at –80°C; the right hemisphere was fixed in Carnoy solution cut coronally at four standard levels and embedded in paraplast. Serial sections (8 μm thick) from each block were stained with hematoxylin-eosin and thioflavine S or incubated with a monoclonal antibody (mAb) to GFAP (Boehringer-Mannheim Germany) (ratio 1:100) or the mAb 3F4 (ratio 1:200) which recognizes an epitope including residues 108 to 111 of hamster PrP. Immunoreactions were revealed by the peroxidase-antiperoxidase method with the use of goat anti-mouse immunoglobulins PAP complex (DAKO Denmark) and 3-3′-diaminobenzidine. Negative control sections were incubated with normal mouse serum as primary antibody. The specificity of PrP immunoreactivity was verified by absorption. The antibody 3F4 was incubated with a synthetic peptide homologous to residues 101 to 119 of human PrP (10 mM) for 1 hour at 37°C and then overnight at 4°C. After centrifugation at 15 000 g for 15 min the supernatant was used as primary antibody.
  22. A 10% (w/v) homogenate of the left cerebral hemisphere from each hamster was prepared in 100 mM NaCl 10 mM EDTA 0.5% NP-40 0.5% sodium deoxycholate and 10 mM tris (pH 7.4). After centrifugation at 1000 g for 10 min the protein concentration in the supernatant was determined by the bicinchoninic acid assay (Pierce USA). Samples equivalent to 100 μg of protein were mixed with equal volumes of twice the concentration of Laemmli sample buffer and incubated with proteinase K (20 μg/ml) for 1 hour at 37°C. Proteolysis was terminated by the addition of phenylmethylsulfonyl fluoride (1 mM final concentration). The samples were fractionated on 12.5% SDS-polyacrylamide minigels under reducing conditions electrophoretically transferred to polyvinylidene difluoride membranes (Immobilon Millipore USA) and probed with the antibody 3F4 (ratio 1:50 000) as described previously (17). Further aliquots of the original samples were probed with mAbs to α- and β-tubulin subunits (Amersham UK) (ratio 1:5000). Immunoreactive bands were visualized with enhanced chemoluminescence (Amersham) and quantified by densitometry with a Mitsubishi Video Copy Processor (Model P68E) a IV-530 Contour Synthesizer (FOR-A Co. Limited France) and the Bio-Profil package of softwares (Vilber-Lourmat France). The specificity of the reactions was checked with the use of normal mouse serum and absorbed 3F4 as primary antibodies. Densitometric data were analyzed according to ANOVA examining the effects of IDX across the two experiments on the resolved optical density of PrP-immunoreactive bands normalized for tubulin. The significance of difference from respective controls was assessed by paired t test.
  23. Total RNA was isolated from brain homogenates of uninfected controls infected controls and IDX-treated hamsters by a single-step method with the use of the ultraspec RNA isolation system (Biotecx). Fifteen μg of RNA from each sample was fractionated by MOPS-EDTA agarose gel electrophoresis and transferred to Hybond-N+ membranes (Amersham). The filters were hybridized with human PrP cDNA that was labeled to a specific activity >1 × 10 8 cpm/μg using [ 32 P]deoxycytidine triphosphate by the random primer labeling procedure (18). The membranes were washed and exposed to film at –70°C. β-actin mRNA was used as an internal standard.
  24. Brown P., Antiviral Chem. Chemother. 1, 75 (1990); (10.1177/095632029000100201) / Antiviral Chem. Chemother. by Brown P. (1990)
  25. ; ___ in Antiviral Agents: The Development and Assessment of Antiviral Chemotherapy H. J. Field Ed. (CRC Press Boca Raton FL 1988) vol. 2 pp. 13–28.
  26. Ehlers B., Diringer H., J. Gen. Virol. 65, 1325 (1984); (10.1099/0022-1317-65-8-1325) / J. Gen. Virol. by Ehlers B. (1984)
  27. Farquhar C. F., Dickinson A. G., ibid. 67, 463 (1986); / ibid. by Farquhar C. F. (1986)
  28. Kimberlin R. H., Walker C. A., Antimicrob. Agents Chemother. 30, 409 (1986); (10.1128/AAC.30.3.409) / Antimicrob. Agents Chemother. by Kimberlin R. H. (1986)
  29. Pocchiari M., Schmittinger S., Masullo C., J. Gen. Virol. 68, 219 (1987) ; (10.1099/0022-1317-68-1-219) / J. Gen. Virol. by Pocchiari M. (1987)
  30. Xi Y. G., Ingrosso L., Ladogana A., Masullo C., Pocchiari M., Nature 356, 598 (1992); (10.1038/356598a0) / Nature by Xi Y. G. (1992)
  31. Kimberlin R. H., Walker C. A., Arch. Virol. 78, 9 (1993); (10.1007/BF01310854) / Arch. Virol. by Kimberlin R. H. (1993)
  32. Adjou K. T., et al., Antimicrob. Agents Chemother. 39, 2810 (1995) . (10.1128/AAC.39.12.2810) / Antimicrob. Agents Chemother. by Adjou K. T. (1995)
  33. Fomelli F., Carsana R., Pollini C., Cancer Res. 47, 5401 (1987). / Cancer Res. by Fomelli F. (1987)
  34. 10.1016/0092-8674(94)90554-1
  35. J. Sambrook E. F. Fritsch T. Maniatis in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press Cold Spring Harbor NY 1989).
  36. We thank R. J. Kascsak for providing the antibody 3F4 L. Frigerio for preparation of histological sections and M. Rochetti for statistical advice. Partially supported by the Italian Ministry of Health Department of Social Services Telethon-Italy (grant E.250) and the Consiglio Nazionale delle Ricerche (grant ST/74).
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 5:45 a.m.)
Deposited 1 year, 7 months ago (Jan. 12, 2024, 11:08 p.m.)
Indexed 4 months, 4 weeks ago (April 4, 2025, 12:04 p.m.)
Issued 28 years, 3 months ago (May 16, 1997)
Published 28 years, 3 months ago (May 16, 1997)
Published Print 28 years, 3 months ago (May 16, 1997)
Funders 0

None

@article{Tagliavini_1997, title={Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters}, volume={276}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.276.5315.1119}, DOI={10.1126/science.276.5315.1119}, number={5315}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Tagliavini, F. and McArthur, R. A. and Canciani, B. and Giaccone, G. and Porro, M. and Bugiani, M. and Lievens, P. M.-J. and Bugiani, O. and Peri, E. and Dall’Ara, P. and Rocchi, M. and Poli, G. and Forloni, G. and Bandiera, T. and Varasi, M. and Suarato, A. and Cassutti, P. and Cervini, M. A. and Lansen, J. and Salmona, M. and Post, C.}, year={1997}, month=may, pages={1119–1121} }